Abstract: The present disclosure is directed to, inter alia, methods of treating a subject suffering from or diagnosed with depression, comprising administering to a subject in need of such treatment an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R1 to R4 are described herein and wherein the compound is administered prior to sleep.

Abstract: The present disclosure is directed to, inter alia, methods of treating a subject suffering from or diagnosed with depression, comprising administering to a subject in need of such treatment an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R1 to R4 are described herein and wherein the compound is administered prior to sleep.

Abstract: The present disclosure is directed to, inter alia, methods of treating a subject suffering from or diagnosed with depression, comprising administering to a subject in need of such treatment an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R1 to R4 are described herein and wherein the compound is administered prior to sleep.

Abstract: The present disclosure is directed to, inter alia, methods of treating a subject suffering from or diagnosed with depression, comprising administering to a subject in need of such treatment an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R1 to R4 are described herein and wherein the compound is administered prior to sleep.

Abstract: The present disclosure is directed to, inter alia, methods of treating a subject suffering from or diagnosed with depression, comprising administering to a subject in need of such treatment an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R1 to R4 are described herein and wherein the compound is administered prior to sleep.

Abstract: The present disclosure is directed to, inter alia, methods of treating a subject suffering from or diagnosed with depression, comprising administering to a subject in need of such treatment an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R1 to R4 are described herein and wherein the compound is administered prior to sleep.

Abstract: The invention relates to VLAN numbering in access networks.

Abstract: VLAN numbering in access networks which bi-directionally connect subscribers and service providers. For an outgoing packet flowing in a direction from a network side to a subscriber side through a network terminator (NT), a port number appearing in a packet header on the network side is not copied by the NT into a header of a corresponding packet applied to the subscriber side, but the NT copies VLAN numbers for the services from the former to the latter packet headers. All services from one specific service provider are delivered to the subscriber through one specific physical port on the subscriber side which corresponds to the port number.

Abstract: A chair comprising a supporting element adapted to tilt about a horizontal axis can be constructed in an ergometrically acceptable way when the supporting element is coupled with the frame through both a torsional spring and a gas spring. In this manner the supporting element can be simply set in the correct position.